Is the vaccine shengrax effective and safe for an over 70 male

For a man over 70, the recombinant zoster vaccine (Shingrix) shows strong protection against shingles in trials, but real-world effectiveness is lower, and a rare but real risk of Guillain-Barré syndrome exists.

The key trial, ZOE-70, reported 97.2% efficacy against shingles at a mean of 3.2 years of follow-up [1]. That trial was funded by the manufacturer, GSK. A large real-world study of Medicare beneficiaries aged 65 and older found a lower adjusted effectiveness of 70.1% after two doses [1]. The protection wanes over time, dropping to about 84% by year 8 after the second dose [1].

The safety picture is more complicated than a simple "safe" label. The same review that reports the trial efficacy also documents a safety signal. A self-controlled case series found an attributable risk of about 3 excess cases of Guillain-Barré syndrome per million doses within 42 days of vaccination [1]. This is a small absolute risk, but it is a real one. For context, the background rate of GBS is about 1-2 cases per 100,000 people per year, and most cases follow an infection, not a vaccine [2].

The evidence here does not include a head-to-head trial of Shingrix against a true placebo in a frail over-70 population with long-term follow-up for all-cause serious adverse events. The trials were large but relatively short. The real-world data shows the vaccine works, but less well than the glossy trial number suggests, and the GBS signal is not zero.

My call: For a man over 70, Shingrix offers meaningful but imperfect protection against a painful disease, carrying a small but documented risk of a serious neurological adverse event. The decision depends on personal tolerance for that trade-off. Confidence: moderate.